Related Experiment Video
Updated: Apr 26, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.3K
Progression rates and sample size estimates for PPMS based on the CLIMB study population.
Kesav Raghavan1, Brian C Healy2, Robert L Carruthers1
1Partners Multiple Sclerosis Center, Brigham and Women's Hospital, USA.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 30, 2014
Summary
Primary progressive multiple sclerosis (PPMS) patients experience faster disability progression than relapsing-onset MS (ROMS) patients. This understanding is crucial for designing effective clinical trials for PPMS.
Area of Science:
- Neurology
- Clinical Research
- Epidemiology
Background:
- Understanding disability progression in primary progressive multiple sclerosis (PPMS) is essential for modern clinical trial design.
- Characterizing contemporary PPMS patient cohorts is vital for accurate research.
Purpose of the Study:
- To define the demographic and clinical features of PPMS patients.
- To evaluate the rate of disability progression in PPMS compared to relapsing-onset MS (ROMS).
Main Methods:
- A longitudinal study compared PPMS (n=73) and ROMS (n=1541) patients.
- Disability progression was assessed using interval-censored survival analysis and time to sustained progression.
Main Results:
- PPMS patients had a later age of onset and different sex ratio compared to ROMS.
- Motor symptoms and spinal cord symptoms at onset were linked to PPMS.
- PPMS showed significantly faster progression to key disability milestones (EDSS 3 and 6) and faster time to sustained progression.
Conclusions:
- The demographic profile of the modern PPMS cohort aligns with previous findings.
- PPMS is characterized by more rapid disability accumulation than ROMS.
- Real-world data on time to sustained progression will aid in developing future PPMS clinical trials.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
16
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:20Longitudinal Research
11.7K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
11.7K